Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe dose increase in homozygous sitosterolemia
NCT00092898Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Oct 2004
- Primary completion
- Sep 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe in sitosterolemia (2 arms), sponsored by Organon & Co. Primary endpoint: Sitosterol concentrations at 26 weeks. Started Oct 2004; status: completed.
02
Drugs
ezetimibe
03
Conditions
sitosterolemia
Beyond the preview
Go deeper on NCT00092898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092898.